Replimune is a high-stakes regulatory binary: RP1 approval could validate a differentiated oncolytic immunotherapy platform, unlock financing, and drive major upside, while another FDA rejection could push the company toward severe dilution or asset liquidation.
Overview
Replimune is a pre-commercial clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies for advanced solid tumors. Its lead asset, RP1, is designed to directly lyse tumors while stimulating systemic anti-tumor immunity, potentially overcoming resistance to checkpoint inhibitors. The company currently has no product revenue and depends on FDA approval of RP1 in anti-PD-1 refractory melanoma. Clinical data suggest durable responses and systemic activity, but the investment case is highly binary, hinging on regulatory acceptance, commercialization execution, and balance-sheet survival.